Cleveland Clinic is launching the Quantum Innovation Catalyzer Program, a chance for start-up companies in healthcare technology and life sciences to gain experience with quantum computing and apply it to their research and development work under expert guidance.Read More
New findings allow researchers to better identify potential problems in blood development, with potential for use in developing treatments for cancer and blood diseases.
Investigators found that patients with ESRD living in areas with lower residential life expectancy had significantly poorer health outcomes and reduced incidence of important processes of care compared to patients living in higher life expectancy areas.
New research provides a critical new element that could soon lead to fully integrated and efficient prosthesis control. The lead investigator explains the backstory and implications.
Cisplatin and CBL0137 work synergistically to attack a combination of three different cellular pathways that contribute to chemotherapy resistance.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A WASP/WAVE actin-cytoskeleton remodeling protein plays a major role in chemoresistance in triple-negative breast cancers.
Researchers will use Microsoft’s HoloLens and an application for the mixed reality technology to visualize surgery in true 3-D.
A study of human cardiac tissue shows that CTGF mediates the profibrotic effects of MAS in cardiac fibroblasts. The findings suggest a promising target for heart failure drug intervention.
By demonstrating the most dramatic reversal of amyloid deposition in an Alzheimer’s disease mouse model to date, a new study gives renewed support to the BACE1 inhibitor class in human trials.
For the first time, research suggests that Akt3 protects against diet-related obesity in a preclinical model by suppressing a mechanism of adipogenesis. Eugene Podrez, MD, PhD, explains.
A new study the Department of Cellular and Molecular Medicine identifies a never-before described survival pathway in cancer stem cells (CSCs) that may serve as a potential target for new triple-negative breast cancer (TNBC) treatment therapies.